Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone intra-erythrocyte therapy in Crohn's disease and ulcerative colitis
2018-004763-31Phase 2Completed
- Sponsor
- EryDel S.p.A.
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) comparing Dex 21-P intra-erythrocyte arm with Placebo intra-erythrocyte arm (2 arms). Started Sep 2019; status: completed.
02
Drugs
dexamethasone sodium phosphate
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2018-004763-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004763-31.